Allergan PLC (AGN)

204.65
NYSE : Health Care
Prev Close 202.66
Day Low/High 201.42 / 209.25
52 Wk Low/High 184.50 / 256.80
Avg Volume 2.07M
Exchange NYSE
Shares Outstanding 334.31M
Market Cap 67.75B
EPS 38.20
P/E Ratio N/A
Div & Yield 2.80 (1.40%)

Latest News

Apple Pullback Warrants Upgrade

Concern over weak iPhone 8 launch is overblown and creating an entry point.

A Deep Dive Into Our Oil, Technology and Healthcare Names

An update on the price action, fundamentals and recent news of a number of portfolio stocks.

Apple Launch Is Still Trying to Get Off the Ground

Concerns about watch, new iPhone aren't putting us off the stock.

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Senator tells Jim Cramer the Federal Reserve should 'step up' and show Americans that it will not stand for companies that defraud consumers.

Centene: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

Michael Neidorff, chairman and CEO of Centene, tells Jim Cramer that the Fidelis merger gives his company scale in the largest states.

The Pitney Bowes Transformation: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Marc Lautenbach, president and CEO of Pitney Bowes, tells Jim Cramer his company is removing complexity from shipping for ecommerce applications in the cloud.

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

Jim Cramer is bullish on Healthcare Trust of America and Marathon Petroleum. But he's cautious about The Trade Desk and CyberArk Software.

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)

Jim Cramer sees a lot of questionable results after the bell, but the enthusiasm -- and the rally -- just keep going every day.

We're Buying More Allergan

Stock dips due to opioid probe of drug companies.

Markets Await Fed Meeting

We're encouraged about our oil stocks.

Stock Observations; Reviewing Equities: Doug Kass' Views

Stock Observations; Reviewing Equities: Doug Kass' Views

Doug Kass shares his thoughts on some key stocks and reviews some equities.

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Patent lawyers are intrigued and competitors will likely challenge, but the move to transfer ownership of the patent to the Saint Regis Mohawk tribe could cause other companies to try a similar tack.

Teva's New CEO Brings This Secret Weapon

Teva's New CEO Brings This Secret Weapon

The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.

Weekly Roundup

Hurricane Irma damage is less than expected, which lifts markets. In the portfolio, we add to one position while updating the ratings on two others.

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab)

Will Allergan's Deal With Tribe Hold Up?

Will Allergan's Deal With Tribe Hold Up?

Answering questions from the biotech mailbag.

Allergan Launches New Brilliant Distinctions® Patient Loyalty Program

Allergan Launches New Brilliant Distinctions® Patient Loyalty Program

Best-in-Class Program with More Than Three Million Members Updated For More Rewarding User Experience Through New Digital Platform

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Jim Cramer says it's a very rare moment when the absence of negatives, however fleeting or relative, creates a stampede of buying.

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Jim Cramer is bullish on Allergan, USG Corp, and Arena Pharmaceuticals.

Irma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI

Irma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI

Here's what you need to know now for Monday, September 11.

Goldman Sachs Could Be Another Negative Tell; Takeaways: Doug Kass' Views

Goldman Sachs Could Be Another Negative Tell; Takeaways: Doug Kass' Views

Doug Kass shares his thoughts on Goldman Sachs as well as running through some of his takeaways and observations.

The Media Is the Message; Allergan Gets Jiggy: Doug Kass' Views

The Media Is the Message; Allergan Gets Jiggy: Doug Kass' Views

Doug Kass shares his thoughts on Comcast, Apple, Disney and a few other companies.

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity

Weekly Roundup

Markets keep an eye on the storms while the Fed has a surprise. We add a name to the portfolio.

Allergan Shares Rise on Novel Patent Pact for Restasis

Allergan Shares Rise on Novel Patent Pact for Restasis

The drugmaker unveiled an agreement that transfers patents for Restasis, Allergan's longstanding dry eye medication, to the Saint Regis Mohawk Tribe, which claims immunity from patent challenges.

2 Small Biotechs Under $5 May Be Bargains

2 Small Biotechs Under $5 May Be Bargains

T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.

TheStreet Quant Rating: C (Hold)